Sage Therapeutics

Showing 6 posts of 6 posts found.

sage_logo

Sage Therapeutics to halve its total workforce in radical cost-cutting move

April 8, 2020
Research and Development, Sales and Marketing Sage Therapeutics, pharma, staff cuts

Sage Therapeutics has revealed a radical restructuring effort to cut costs and “enable the company to advance its corporate strategy …

sage_logo

Sage Therapeutics’ depression drug falls short at Phase 3

December 6, 2019
Medical Communications, Research and Development Sage Therapeutics, major depressive disorder, pharma, trial failure

Sage Therapeutics has announced that its candidate SAGE-217 flopped in Phase 3 trials investigating its efficacy in symptom reduction for …

FDA approves first-ever postpartum depression therapy: Sage Therapeutics’ Zulresso

March 20, 2019
Research and Development, Sales and Marketing FDA, Sage Therapeutics, depression, pharma, postpartum depression

The FDA has announced its decision to approve Sage Therapeutics’ intraveneous injection Zulresso (brexanolone), marking the first authorisation of a …

upwards_graph

Sage Therapeutics stock pops on depression P2 results

December 8, 2017
Medical Communications, Research and Development Sage Therapeutics, biotech, drugs, pharma, pharmaceutical

Sage Therapeutics’ stock rocketed after it announced that Phase 2 results for its treatment for major depressive disorder (MDD) were …

child-2916844_960_720

Sage scores good but not great P3 postpartum depression drug results

November 10, 2017
Medical Communications, Research and Development Sage Therapeutics, biotech, drugs, pharma, pharmaceutical

Sage Therapeutics share price soared 50% on the release that its two Phase 3 trials of brexanolone showed statistically significant …

Latest content